Mental Health Blogs

Eli Lilly announced its third quarter results today. Cymbalta sales are way up:

“Lilly’s biggest drug, Zyprexa, posted sales of $1.2 billion, up 2.8%. Higher selling prices offset lower demand in the U.S. Demand increased outside the U.S. Sales of antidepressant Cymbalta rose 10% to $790 million.”

A 10 percent increase over the same quarter last year is pretty significant. While I’m not clear on whether Lilly upped Cymbalta prices in the last year (which would account for a portion of the revenue increase if they had), it looks as though more scrips for this tricky anti-depressant are being written. Whether they are for depression or for pain indications isn’t clear to me at all.

It looks like Cymbalta could top $3 billion in sales this year.

Go to Source

Related posts:

1. Abilify Sales Way Up
2. Wyeth Again Fails To Detail Pristiq Sales
3. FDA Warns Lilly Over False, Misleading Cymbalta Ads
4. Cymbalta Gets FDA Approval For Anxiety Maintenance Treatment
5. Lexapro Sales Stabilized By Lexapro Sales To Teens